When does Europe exclusivity for GATEX (somatrogon) end in the EU?
I can’t determine the exact “revestive”/exclusivity end date from the information provided here. The EU exclusivity date depends on which protection you mean (for example, data/market exclusivity versus patent expiry) and which specific product authorization refers to (brand name and active ingredient).
What “exclusivity date” could users mean for an EU medicine like GATEX?
In EU medicines, “exclusivity” can refer to different timelines, most commonly:
- Regulatory market exclusivity/data protection periods tied to the first marketing authorization in the EU (often discussed as “8+2+1” style protection, but the exact numbers depend on circumstances).
- Patent expiry (which may be earlier or later than regulatory exclusivity).
- Exclusivity extensions if the company qualifies for certain regulatory conditions.
Without the specific reference (the EU product authorization and which exclusivity type you want), there isn’t enough detail to provide a single date.
How to get the exact EU date quickly (and what I need from you)
If you share either of the following, I can give you the precise Europe exclusivity end date you’re looking for:
1. The active ingredient spelling (e.g., somatrogon), and whether the question is about market exclusivity or patent expiry.
2. A link or document name you’re using (for example, an EPAR/EMA product page, an EUIPO/registry page, or a patent register entry).
Reply with the active ingredient and the exclusivity type (or paste the source you have), and I’ll pinpoint the end date for Europe.
Common edge cases that change the “exclusivity” date
Even for the same brand, the date can differ if:
- There are multiple strengths/formulations (each can have separate regulatory milestones).
- The EU authorization used for the calculation is a new indication or new legal basis rather than the original one.
- Paediatric / other regulatory incentives apply, shifting timelines.
- Patents covering the product are different in scope and expire at different times.
If you tell me which exact product authorization you mean, I’ll align the date to the correct exclusivity mechanism.
Sources cited: none (no source material was provided to extract a date).